BR112018069303A2 - método para tratamento de uma infecção - Google Patents

método para tratamento de uma infecção

Info

Publication number
BR112018069303A2
BR112018069303A2 BR112018069303A BR112018069303A BR112018069303A2 BR 112018069303 A2 BR112018069303 A2 BR 112018069303A2 BR 112018069303 A BR112018069303 A BR 112018069303A BR 112018069303 A BR112018069303 A BR 112018069303A BR 112018069303 A2 BR112018069303 A2 BR 112018069303A2
Authority
BR
Brazil
Prior art keywords
infection
treating
difficile
preventing
methods
Prior art date
Application number
BR112018069303A
Other languages
English (en)
Portuguese (pt)
Inventor
P Draper Michael
Ken Tanaka S
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Priority to BR122024000249-3A priority Critical patent/BR122024000249A2/pt
Publication of BR112018069303A2 publication Critical patent/BR112018069303A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018069303A 2016-03-24 2017-03-24 método para tratamento de uma infecção BR112018069303A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122024000249-3A BR122024000249A2 (pt) 2016-03-24 2017-03-24 Uso de um composto ou um sal do mesmo

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Publications (1)

Publication Number Publication Date
BR112018069303A2 true BR112018069303A2 (pt) 2019-01-22

Family

ID=59900751

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018069303A BR112018069303A2 (pt) 2016-03-24 2017-03-24 método para tratamento de uma infecção
BR122024000249-3A BR122024000249A2 (pt) 2016-03-24 2017-03-24 Uso de um composto ou um sal do mesmo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122024000249-3A BR122024000249A2 (pt) 2016-03-24 2017-03-24 Uso de um composto ou um sal do mesmo

Country Status (13)

Country Link
US (3) US20170319603A1 (enExample)
EP (1) EP3432891A4 (enExample)
JP (3) JP7458706B2 (enExample)
CN (2) CN119454720A (enExample)
AU (3) AU2017238644B2 (enExample)
BR (2) BR112018069303A2 (enExample)
CA (1) CA3018872A1 (enExample)
MX (2) MX2018011413A (enExample)
MY (1) MY197627A (enExample)
PH (1) PH12018502020A1 (enExample)
RU (1) RU2751509C1 (enExample)
SG (2) SG11201808246SA (enExample)
WO (1) WO2017165729A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
CN110087655A (zh) * 2016-11-01 2019-08-02 帕拉特克药品公司 9-氨基甲基米诺环素化合物及其在治疗社区获得性细菌性肺炎(cabp)中的用途
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
EP3846805A4 (en) * 2018-09-04 2022-08-24 Paratek Pharmaceuticals, Inc. Methods of treating mycobacterial infections using tetracycline compounds
CN112823014A (zh) * 2018-10-10 2021-05-18 营养株式会社 艰难梭菌感染的预防和/或治疗剂
AU2021288202A1 (en) * 2020-06-11 2022-12-08 Paratek Pharmaceuticals Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113614A1 (en) * 1991-07-24 1993-02-04 Scott Donald Whalen Antimicrobial treatment methods and compositions
MXPA03000055A (es) * 2000-07-07 2003-07-14 Tufts College Compuestos de monociclina sustituidos en posicion 9..
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332546A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
JP2009521456A (ja) * 2005-12-22 2009-06-04 ワイス チゲサイクリンでの胃腸管感染症の治療法
EP1991236A2 (en) * 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202021946A (zh) * 2008-05-19 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
AU2010213773B2 (en) * 2009-02-11 2014-07-17 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
KR102222273B1 (ko) * 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection

Also Published As

Publication number Publication date
EP3432891A4 (en) 2019-10-30
US20250049819A1 (en) 2025-02-13
WO2017165729A1 (en) 2017-09-28
EP3432891A1 (en) 2019-01-30
SG10201913559VA (en) 2020-02-27
US20170319603A1 (en) 2017-11-09
JP2019509318A (ja) 2019-04-04
CA3018872A1 (en) 2017-09-28
JP2024023187A (ja) 2024-02-21
CN119454720A (zh) 2025-02-18
MY197627A (en) 2023-06-29
PH12018502020A1 (en) 2019-07-15
SG11201808246SA (en) 2018-10-30
CN109152789A (zh) 2019-01-04
JP7458706B2 (ja) 2024-04-01
US20200281948A1 (en) 2020-09-10
AU2025202020A1 (en) 2025-04-10
AU2023200798A1 (en) 2023-03-09
JP2022115985A (ja) 2022-08-09
MX2018011413A (es) 2019-01-10
AU2017238644B2 (en) 2022-12-15
BR122024000249A2 (pt) 2024-02-27
RU2751509C1 (ru) 2021-07-14
AU2017238644A1 (en) 2018-10-25
MX2023004969A (es) 2023-05-24

Similar Documents

Publication Publication Date Title
BR112018069303A2 (pt) método para tratamento de uma infecção
IL281566A (en) Methods and systems for diagnosing and treating health ailments
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2018007987A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
IL311121A (en) Sterilisation method
MX2018015522A (es) Tratamiento de infeccion por clostridium difficile.
EP3407820A4 (en) Automated dental treatment system
EP4049580C0 (en) METHODS AND SYSTEM FOR MONITORING AMETROPIA TREATMENT
BR112018006696A2 (pt) métodos e sistemas para obter óleo a partir de uma composição de vinhoto
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
PT3265087T (pt) Método de tratamento com tradipitant
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
LT3728410T (lt) Lignoceliuliozės biomasės apdorojimo būdas
MX2019003035A (es) Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
DK3294769T3 (da) Behandling for multipelt myelom (mm)
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
UY36286A (es) Tratamientos médicos basados en anamorelina
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
DK3717011T5 (da) Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
BR112017008097A2 (pt) método para tratar condições oculares
EP3624819A4 (en) Methods of treatment for cervical dystonia
PT3630968T (pt) Enzimas para análise de glicanos
EP3347884A4 (en) PRIVACY-MAINTENANCE MONITORING
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024000249-3 PROTOCOLO 870240001490 EM 05/01/2024 16:41.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]